Detailed Narrative
Strong Q1 FY26 Performance Driven by CRDM
Anthem Biosciences reported a robust start to FY26 with consolidated revenue reaching INR 540 crores for the quarter. The CRDM business was the primary growth engine, contributing INR 452.7 crores, while specialty ingredients added INR 87.5 crores. This performance translated into an EBITDA of INR 214.3 crores, achieving a healthy margin of 38%, and a PAT of INR 13.58 crores with a 24% margin. The company ended the quarter with a strong net cash position of INR 784.8 crores.
Proactive Capacity Expansion Underway
The company continues its strategic capacity expansion, adding 54 kiloliters of custom synthesis capacity in Q1 FY26. An additional 76 kiloliters for custom synthesis in Unit 2 and 25 kiloliters in NeoAnthem are slated for completion by calendar year-end and H1 FY26, respectively. Furthermore, 40 kiloliters of fermentation capacity in NeoAnthem is also expected by calendar year-end. Groundbreaking for Unit 4 expansion occurred in Q1 FY26, with further details on capacity additions anticipated in the coming months⏳.
Pipeline Progression and New Modalities Focus
Anthem successfully advanced two Phase 3 molecules to commercial status, increasing its commercial portfolio from 10 to 12 products, while the Phase 3 pipeline reduced from 10 to 8. The company is actively involved in new modalities such as ADCs, peptides, and RNA products, having commissioned commercial-scale facilities for ADCs and peptides. While full capabilities exist in the ADC space, no projects have reached commercialization yet, but management expresses optimism for future breakthroughs.
Strategic Outlook and Growth Drivers
Management reiterated its long-term outlook of achieving approximately 20% year-on-year growth for FY26 and beyond, aligning with its historical 10-year CAGR of 22%. The growth is expected to be driven by the ramping up of CRDM revenue streams and increased demand for existing commercial products. Anthem is also positioning itself as a serious player in the GLP-1 space, actively engaging with customers and developing solutions, anticipating it to be a significant future growth driver.
Navigating Pricing Environment and Geopolitical Uncertainties
Despite global discussions around MFN policies and drug pricing, Anthem has not experienced undue pricing pressure from its customers. Management emphasized the company's ability to adapt to uncertain political and economic environments, drawing on its 20-year track record of navigating crises. The company believes potential tariffs would have limited direct impact due to its supply chain structure, and establishing a manufacturing facility in the US is considered a very long-term and challenging prospect.
Capital Allocation and Funding Strategy
Anthem's capital expenditure for Unit 2 and 3 is committed at approximately INR 150 crores, with Unit 4 planning in early stages. The company plans to fund its capacity expansions primarily through its substantial net cash position of INR 784.8 crores. This strong liquidity allows Anthem to invest in growth initiatives without relying heavily on external borrowings, maintaining a positive net cash position.